The MA-17 trial was designed to compare the efficacy and safety of extended adjuvant therapy with letrozole for 5 years in postmenopausal women with ER-positive early breast cancer who completed 5 year treatment of adjuvant tamoxifen Results have shown superior DFS in the letrozole arm compared with placebo.
.png)
.png)